| PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Y Nagata, KH Lan, X Zhou, M Tan, FJ Esteva, AA Sahin, KS Klos, P Li, ... Cancer cell 6 (2), 117-127, 2004 | 2279 | 2004 |
| Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer R Nahta, D Yu, MC Hung, GN Hortobagyi, FJ Esteva Nature clinical practice Oncology 3 (5), 269-280, 2006 | 1205 | 2006 |
| Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth L Zhang, S Zhang, J Yao, FJ Lowery, Q Zhang, WC Huang, P Li, M Li, ... Nature 527 (7576), 100-104, 2015 | 1200 | 2015 |
| Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity CW Li, SO Lim, W Xia, HH Lee, LC Chan, CW Kuo, KH Khoo, SS Chang, ... Nature communications 7 (1), 12632, 2016 | 955 | 2016 |
| Tumor microenvironment as a therapeutic target in cancer Y Xiao, D Yu Pharmacology & therapeutics 221, 107753, 2021 | 933 | 2021 |
| p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs CJ Chang, CH Chao, W Xia, JY Yang, Y Xiong, CW Li, WH Yu, ... Nature cell biology 13 (3), 317-323, 2011 | 889 | 2011 |
| ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation JY Yang, CS Zong, W Xia, H Yamaguchi, Q Ding, X Xie, JY Lang, CC Lai, ... Nature cell biology 10 (2), 138-148, 2008 | 802 | 2008 |
| Exosomes in cancer development, metastasis, and immunity L Zhang, D Yu Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1871 (2), 455-468, 2019 | 772 | 2019 |
| Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis YM Li, Y Pan, Y Wei, X Cheng, BP Zhou, M Tan, X Zhou, W Xia, ... Cancer cell 6 (5), 459-469, 2004 | 687 | 2004 |
| Deubiquitination and stabilization of PD-L1 by CSN5 SO Lim, CW Li, W Xia, JH Cha, LC Chan, Y Wu, SS Chang, WC Lin, ... Cancer cell 30 (6), 925-939, 2016 | 666 | 2016 |
| Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways S Zhang, WC Huang, P Li, H Guo, SB Poh, SW Brady, Y Xiong, LM Tseng, ... Nature medicine 17 (4), 461-469, 2011 | 622 | 2011 |
| Overexpression of ErbB2 in cancer and ErbB2-targeting strategies D Yu, MC Hung Oncogene 19 (53), 6115-6121, 2000 | 550 | 2000 |
| Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers X Zhou, M Tan, V Stone Hawthorne, KS Klos, KH Lan, Y Yang, W Yang, ... Clinical Cancer Research 10 (20), 6779-6788, 2004 | 475 | 2004 |
| Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase D Yu, T Jing, B Liu, J Yao, M Tan, TJ McDonnell, MC Hung Molecular cell 2 (5), 581-591, 1998 | 473 | 1998 |
| The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis CH Chan, CF Li, WL Yang, Y Gao, SW Lee, Z Feng, HY Huang, KKC Tsai, ... Cell 149 (5), 1098-1111, 2012 | 434 | 2012 |
| PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer FJ Esteva, H Guo, S Zhang, C Santa-Maria, S Stone, JS Lanchbury, ... The American journal of pathology 177 (4), 1647-1656, 2010 | 377 | 2010 |
| Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy R Yang, L Sun, CF Li, YH Wang, J Yao, H Li, M Yan, WC Chang, JM Hsu, ... Nature communications 12 (1), 832, 2021 | 366 | 2021 |
| Enhanced c-erbB-2/neu Expression in Human Ovarian Cancer Cells Correlates with More Severe Malignancy That Can Be Suppressed by E1A D Yu, JK Wolf, M Scanlon, JE Price, MC Hung Cancer research 53 (4), 891-898, 1993 | 365 | 1993 |
| A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas JD Henson, JA Hannay, SW McCarthy, JA Royds, TR Yeager, ... Clinical cancer research 11 (1), 217-225, 2005 | 359 | 2005 |
| Targeting Src family kinases in anti-cancer therapies: turning promise into triumph S Zhang, D Yu Trends in pharmacological sciences 33 (3), 122-128, 2012 | 358 | 2012 |
